Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting

Introduction Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insufficient real-world data supporting shortening of t...

Full description

Bibliographic Details
Main Authors: Dorota Zarębska-Michaluk, Anna Piekarska, Jerzy Jaroszewicz, Jakub Klapaczyński, Marek Sitko, Magdalena Tudrujek-Zdunek, Krzysztof Tomasiewicz, Teresa Belica-Wdowik, Paweł Pabjan, Beata Lorenc, Agnieszka Czauż-Andrzejuk, Olga Tronina, Rafał Krygier, Witold Dobracki, Iwona Buczyńska, Krzysztof A. Simon, Dorota Dybowska, Waldemar Halota, Małgorzata Pawłowska, Jolanta Citko, Łukasz Laurans, Włodzimierz Mazur, Ewa Janczewska, Łukasz Socha, Zbigniew Deroń, Hanna Berak, Robert Flisiak
Format: Article
Language:English
Published: Termedia Publishing House 2019-07-01
Series:Archives of Medical Science
Subjects:
hepatitis c
sofosbuvir
genotype 1
ledipasvir
treatment-naïve
Online Access:https://www.archivesofmedicalscience.com/Efficacy-of-8-versus-12-week-treatment-with-ledipasvir-sofosbuvir-in-chronic-hepatitis,109852,0,2.html

Internet

https://www.archivesofmedicalscience.com/Efficacy-of-8-versus-12-week-treatment-with-ledipasvir-sofosbuvir-in-chronic-hepatitis,109852,0,2.html

Similar Items